Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(7), С. 2959 - 2959
Опубликована: Март 25, 2025
Metabolic-dysfunction-associated
steatotic
liver
disease
(MASLD),
previously
known
as
non-alcoholic
fatty
(NAFLD),
is
a
highly
prevalent
metabolic
disorder
characterized
by
hepatic
steatosis
in
conjunction
with
at
least
one
cardiometabolic
risk
factor,
such
obesity,
type
2
diabetes,
hypertension,
or
dyslipidemia.
As
global
rates
of
obesity
and
syndrome
continue
to
rise,
MASLD
becoming
major
public
health
concern,
projections
indicating
substantial
increase
prevalence
over
the
coming
decades.
The
spectrum
ranges
from
simple
metabolic-dysfunction-associated
steatohepatitis
(MASH),
fibrosis,
cirrhosis,
hepatocellular
carcinoma,
contributing
significant
morbidity
mortality
worldwide.
This
review
delves
into
molecular
mechanisms
driving
pathogenesis,
including
dysregulation
lipid
metabolism,
chronic
inflammation,
oxidative
stress,
mitochondrial
dysfunction,
gut
microbiota
alterations.
Recent
advances
research
have
highlighted
role
genetic
epigenetic
factors
progression,
well
novel
therapeutic
targets
peroxisome
proliferator-activated
receptors
(PPARs),
fibroblast
growth
factors,
thyroid
hormone
receptor
beta
agonists.
Given
multifaceted
nature
MASLD,
multidisciplinary
approach
integrating
early
diagnosis,
insights,
lifestyle
interventions,
personalized
therapies
critical.
underscores
urgent
need
for
continued
innovative
treatment
strategies
precision
medicine
approaches
halt
progression
improve
patient
outcomes.
Язык: Английский
RNA Modification in Metabolism
MedComm,
Год журнала:
2025,
Номер
6(3)
Опубликована: Март 1, 2025
ABSTRACT
Epigenetic
regulation
in
disease
development
has
been
witnessed
within
this
decade.
RNA
methylation
is
the
predominant
form
of
epigenetic
regulation,
and
most
prevalent
modification
N6‐methyladenosine
(m
6
A).
Recently,
emerged
as
a
potential
target
for
treatment.
posttranscriptional
gene
expression
that
involved
both
physiological
pathological
processes.
Evidence
suggests
m
A
significantly
affects
metabolism,
its
abnormal
changes
have
observed
variety
diseases.
Metabolic
diseases
are
series
caused
by
metabolic
processes
body,
common
include
diabetes
mellitus,
obesity,
nonalcoholic
fatty
liver
disease,
etc.;
although
pathogenesis
these
differs
from
each
other
to
current
understanding,
recent
studies
suggested
pivotal
role
modulating
diseases,
A‐based
drug
on
agenda.
This
paper
reviewed
understanding
hoping
provide
systematic
information
those
area.
Язык: Английский